-5%
Prostanor 8 is an alpha-adrenergic antagonist prescribed for the treatment of benign prostatic hyperplasia (BPH). It helps alleviate symptoms such as difficulty in urination by relaxing the muscles around the bladder exit and prostate gland, making urination easier. However, it does not reduce the actual size of the prostate.
Benign prostatic hyperplasia (BPH) is a prevalent condition among aging men and a leading cause of lower urinary tract symptoms (LUTS). Its progression is often linked to bladder outflow obstruction, which may present in both emergency surgical settings and outpatient care. This discussion examines the natural progression of BPH and underscores the critical role of an interprofessional healthcare team in its assessment and management.
Participants will gain insight into key terms such as benign prostatic hyperplasia, benign prostatic enlargement (BPE), and bladder outlet obstruction, clarifying their distinct yet interconnected meanings. They will develop a thorough understanding of BPH, its clinical significance, and evidence-based diagnostic and therapeutic approaches. This knowledge will enable healthcare providers and interdisciplinary team members to optimize patient care and treatment outcomes.